Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20067682 | 0.81 | CNR2 (0.33) | CNR2ERAP2LNPEPERAP1GHSR | |
| SCHEMBL24722847 | 0.81 | GLP1R (0.48) | GLP1RTLR2CCKARCCKBR | |
| SCHEMBL12892953 | 0.79 | ROCK2 (0.44) | GLP1RTLR2 | |
| SCHEMBL13783677 | 0.79 | GLP1R (0.41) | GLP1RCCKARCCKBR | |
| SCHEMBL10054212 | 0.79 | GLP1R (0.39) | GLP1RTLR2CCKARCCKBR | |
| SCHEMBL10054210 | 0.79 | GLP1R (0.39) | GLP1RTLR2CCKARCCKBR | |
| SCHEMBL15096515 | 0.78 | CNR2 (0.45) | CNR2 | |
| SCHEMBL22807658 | 0.78 | GLP1R (0.43) | GLP1R | |
| SCHEMBL13553377 | 0.78 | ERAP2 (0.37) | GLP1RTLR2CNR2ERAP2LNPEP | |
| SCHEMBL22140639 | 0.77 | MGLL (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045428-A1 | LIGAND-TARGETED MOLECULES AND METHODS THEREOF | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045428-A1 | LIGAND-TARGETED MOLECULES AND METHODS THEREOF | HLCS, PAICS, CLTC | GLP1R 2357/4885TLR2 250/4885CNR2 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.